Why is degarelix used instead of a GnRH agonist?

As an antagonist it suppresses testosterone rapidly and without the initial testosterone flare agonists cause, so no antiandrogen flare cover is needed at initiation.

How fast does degarelix lower testosterone?

In the pivotal phase III trial it drove testosterone to castrate levels within a few days, faster than leuprolide.

What is the most common side effect?

Injection-site reactions such as pain, redness, or swelling are the most characteristic effect; hot flashes and other androgen-deprivation effects also occur.

Is degarelix something a person can use without a doctor?

No. It is an oncology drug administered by a healthcare professional with ongoing testosterone and PSA monitoring; there is no legitimate self-directed use.

EMA-approvedaka Firmagon

Degarelix — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Degarelix (also known as Firmagon) is a peptide catalogued under Sexual Health (GnRH antagonist). It is described as: GnRH receptor antagonist. Documented context: Prostate cancer. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Degarelix?

Degarelix (marketed as Firmagon) is a synthetic GnRH receptor antagonist given as a subcutaneous depot, approved by the FDA (2008) and EMA (2009) for the treatment of advanced (hormone-dependent) prostate cancer.

Its evidence base is strong and human, anchored by the pivotal CS21 phase III randomized trial versus leuprolide plus multiple extension and pooled analyses.

It is an oncology prescription drug used only under specialist supervision.

How does Degarelix work?

Degarelix directly blocks pituitary GnRH receptors, producing rapid suppression of LH, FSH, and consequently testosterone to castrate levels.

Unlike GnRH agonists such as leuprolide, it causes no initial testosterone surge (clinical flare), so no antiandrogen flare-protection is needed at the start of therapy.

What does the research say about Degarelix?

Degarelix lowers testosterone to castrate levels faster than the GnRH agonist leuprolide and without the testosterone flare, in the pivotal 12-month phase III trial. ^[1]
A pooled analysis of five randomized trials suggested improved disease-control outcomes such as PSA progression-free survival with degarelix versus LHRH agonists. ^[4]
Long-term extension data showed sustained testosterone and PSA suppression, and crossover from leuprolide to degarelix was associated with favorable PSA control. ^[2]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer — Klotz L et al., BJU International 2008. (Phase III randomized controlled trial (CS21, vs leuprolide))
[2] A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer — Crawford ED et al., Journal of Urology 2011. (Phase III extension randomized trial (crossover))
[3] Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix — Crawford ED et al., Urology 2014. (Phase III extension randomized trial (5-year))
[4] Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists — Klotz L et al., European Urology 2014. (Pooled analysis of five randomized trials)
[5] The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients — Damber JE et al., Urology 2012. (Phase III randomized controlled trial (subanalysis))
[6] Degarelix: a review of its use in patients with prostate cancer — Carter NJ et al., Drugs 2014. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: it is given as a subcutaneous depot with a higher initial loading dose followed by maintenance injections at regular intervals, administered by a healthcare professional.

Dose, interval, and treatment decisions are made by an oncology or urology specialist as part of prostate-cancer management.

Side effects & safety profile

The most characteristic adverse effect is injection-site reactions (pain, erythema, swelling, or nodules), which are more frequent than with intramuscular agonist depots and are usually mild-to-moderate and transient.

Class effects of androgen-deprivation apply, including hot flashes, weight gain, and increased hepatic transaminases; QT-interval prolongation is a labeled class consideration.

It is used strictly within oncology care; there is no legitimate non-medical use, and it requires monitoring of testosterone, PSA, and tolerability.

Stacking & combinations

It is used as part of physician-directed prostate-cancer treatment and is not intended for combination outside supervised oncology protocols.

Finding Degarelix vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved by the FDA and EMA for the treatment of advanced hormone-dependent prostate cancer.

References

[1] The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer — Klotz L et al., BJU International 2008. PMID: 19035858. View sourceStudy: Phase III randomized controlled trial (CS21, vs leuprolide)Degarelix achieved faster testosterone suppression without flare and non-inferior 12-month castration maintenance versus leuprolide.
[2] A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer — Crawford ED et al., Journal of Urology 2011. PMID: 21788033. View sourceStudy: Phase III extension randomized trial (crossover)Sustained suppression continued on degarelix, and switching from leuprolide to degarelix showed favorable PSA control.
[3] Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix — Crawford ED et al., Urology 2014. PMID: 24661333. View sourceStudy: Phase III extension randomized trial (5-year)Degarelix maintained testosterone and PSA suppression with acceptable tolerability over 5 years.
[4] Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists — Klotz L et al., European Urology 2014. PMID: 24440304. View sourceStudy: Pooled analysis of five randomized trialsPooled data suggested improved PSA progression-free and other disease-control outcomes with degarelix versus agonists.
[5] The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients — Damber JE et al., Urology 2012. PMID: 22748873. View sourceStudy: Phase III randomized controlled trial (subanalysis)Degarelix suppressed testosterone effectively across baseline testosterone levels without flare.
[6] Degarelix: a review of its use in patients with prostate cancer — Carter NJ et al., Drugs 2014. PMID: 24756432. View sourceStudy: Narrative reviewConcludes degarelix offers rapid, flare-free testosterone suppression with efficacy comparable to agonists and notable injection-site reactions.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.